Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, +17

Journal of Clinical Oncology

The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled Trial1

Brian W. Walsh, Sofia Paul, Robert A. Wild, +4

The Journal of Clinical Endocrinology & Metabolism

GynecologyMenopausal Hormone TherapyPharmacotherapyMetabolic SyndromeHealthy Postmenopausal Women +14

Design and methods of the Raloxifene Use for The Heart (RUTH) study

Lori Mosca, Elizabeth Barrett‐Connor, Nanette K. Wenger, +8

The American Journal of Cardiology

Heart FailureRaloxifene UseCardiovascular DiseaseMedicinePharmacotherapy +5

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, +17

Journal of Clinical Oncology

Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Glen J. Weiss, Corey J. Langer, Rafael Rosell, +8

Journal of Clinical Oncology

Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles1

Valerie L. Baker, Michael Draper, Sofia Paul, +4

The Journal of Clinical Endocrinology & Metabolism

Hormonal ContraceptiveGynecologyPharmacotherapyMenstrual CycleRaloxifene Hydrochloride +15

Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis

Jean-Louis Pujol, Sofia Paul, Nadia Chouaki, +4

Journal of Thoracic Oncology

OncologyRisk-benefit AnalysisMedicineMetronomic TherapyPemetrexed Compared +5

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors

Sunil Sharma, Joachim Beck, Monica Mita, +5

Investigational New Drugs

Lymphoid NeoplasiaSurgical OncologySolid TumorsMedicineIntravenous Panobinostat +5

Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design

Ajay K. Nooka, Katja Weisel, Niels W.C.J. van de Donk, +21

Future Oncology

Targeting <i>RARA</i> overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Stéphane de Botton, Thomas Cluzeau, Carlos E. Vigil, +26

Blood Advances

Mixed-phenotype Acute LeukemiaImmunologyNovel ApproachPharmacotherapyOral Tamibarotene +22